BAN 2401

Drug Profile

BAN 2401

Alternative Names: BAN2401

Latest Information Update: 08 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioArctic Neuroscience
  • Developer BioArctic; Eisai Co Ltd
  • Class Antidementias; Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Preclinical Brain injuries; Down syndrome

Most Recent Events

  • 25 Jul 2018 Updated efficacy and adverse events data from a phase IIb trial in Alzheimer's disease released by BioArctic
  • 22 Jul 2018 Additional efficacy data from a phase IIb trial in Alzheimer's disease presented at the Alzheimer's Association International Conference-2018 (AAIC-2018)
  • 19 Jul 2018 Eisai completes a phase II trial in Alzheimer's disease (Early-stage disease) in USA, United Kingdom, Germany, Italy, Netherlands, Sweden, Spain, Canada, France, and South Korea (IV) (NCT01767311)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top